68Ga‐PSMA‐PET/CT staging prior to definitive radiation treatment for prostate cancer
暂无分享,去创建一个
T. Eade | A. Kneebone | G. Schembri | E. Hsiao | G. Hruby | L. Emmett | Linxin Guo | K. Byrne | B. Ho | Carol Kwong | J. Hunter | C. Kwong
[1] T. Eade,et al. Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Fabrizio Bergesio,et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[3] P. Roach,et al. Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study , 2017 .
[4] P. Mulders,et al. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model , 2017, The Journal of Nuclear Medicine.
[5] P. Stricker,et al. Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer , 2017, BJU international.
[6] P. Stricker,et al. 68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.
[7] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[8] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[9] T. Eade,et al. Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.